FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
May 24, 2019 16:12 ET
|
Novartis Pharma AG
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone...
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
May 24, 2019 12:42 ET
|
Novartis Pharma AG
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD...
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
May 24, 2019 12:30 ET
|
Novartis Pharma AG
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age...
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care
May 08, 2019 18:20 ET
|
Novartis Pharma AG
Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline...
Novartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben
April 24, 2019 01:00 ET
|
Novartis Pharma AG
Die Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2] ...
Novartis entame 2019 avec une forte croissance des ventes et une hausse à deux chiffres du résultat opérationnel core[1], le lancement de Mayzent et le spin-off d'Alcon; profit annuel revu à la hausse
April 24, 2019 01:00 ET
|
Novartis Pharma AG
La transformation en une société axée sur les médicaments a continué avec le spin-off d'Alcon; les commentaires ci-après ne concernent que les activités poursuivies[2] Chiffre d'affaires net des...
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
April 24, 2019 01:00 ET
|
Novartis Pharma AG
Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by...
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
March 26, 2019 19:33 ET
|
Novartis Pharma AG
Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients...
Novartis plans for Alcon spin-off on April 9, 2019
March 22, 2019 02:00 ET
|
Novartis Pharma AG
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange...
Novartis announces change in Sandoz leadership
March 14, 2019 02:15 ET
|
Novartis Pharma AG
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced...